Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The SUPRAMAX-study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)

NCT06118723 is registered in ClinicalTrials.gov with Jasper Gerritsen as lead sponsor.

NCT NCT06118723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06118723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The SUPRAMAX-study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Lead sponsor
Jasper Gerritsen
Phase
Observational
Overall status
Recruiting
Start date
January 1, 2022
Completion date
January 1, 2028
Enrollment
784 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, grade iii, astrocytoma, grade iv, astrocytoma, malignant, brain neoplasm, malignant, brain neoplasm, primary, brain neoplasms, brain neoplasms, adult, glioblastoma, glioblastoma multiforme, adult, glioblastoma, idh-mutant, glioblastoma, idh-wildtype, high-grade glioma